Abstract
Introduction
The p27 kip1 protein is a member of a family of CDK inhibitors (CDKIs) and plays an important role in multiple fundamental cellular processes and in the pathogenesis of human malignancies, with roles in cell proliferation, cell senescence, cell differentiation, migration, and invasion [1] . P27 kip1 is frequently inactivated in human cancers through accelerated proteolysis, and reduced p27 kip1 expression has been shown to be associated with poor prognosis in a variety of human malignancies [2] , whereas restoration of p27 kip1 levels can inhibit tumor growth and progression [3, 4] . Although it has been shown that p27 kip1 expression is regulated primarily at the posttranscriptional level [5] [6] [7] , the mechanism of p27 kip1 reduction in cancer cells is still unclear. Identifying new pathways and molecules which regulate p27 expression is therefore critical for developing cancer treatments through restoration of p27 levels.
SIRT1 is a nicotinamide adenine dinucleotide (NAD)-dependent non-histone and histone deacetylase that has been reported to play an important role in a variety of physiological processes including aging, DNA repair, apoptosis and cell senescence [8] [9] [10] . SIRT1 overexpression has been shown to be correlated with advanced stages or poor prognosis in many cancer types [11] [12] [13] , and recently there is growing evidence strongly implicating an important role for SIRT1 in cancer growth and progression [14] [15] [16] [17] [18] [19] . In addition, several cellular proteins, such as p53, Foxo3, and E2F, have been identified to play an important role in SIRT1-mediated cancer cell survival [10] . P53 has been shown as an important target of SIRT1 to suppress apoptosis [20] ; however, many studies
show that SIRT1 regulates cancer cell growth regardless of p53 status [21] [22] [23] . The specific mechanism of SIRT1 regulating cancer cell growth and survival is largely unknown.
Recently, several studies have indicated that p27 kip1 may be a downstream target of SIRT1 [24, 25] . In particular, it has been established that p27 kip1 downregulation is consistently associated with poor prognosis in non-small cell lung cancer (NSCLC) [26] [27] [28] and similarly, SIRT1 overexpression is significantly associated with unfavorable clinicopathological factors, including high pathological T-stage and lymph node metastasis in NSCLC [29, 30] . Studies have also shown that SIRT1 inhibition suppresses NSCLC growth [25, [31] [32] [33] , and SIRT1 knock-in in transgenic mice facilitates endothelial cell branching to increase vessel density and lung tumor growth [31] . In addition, SIRT1 activation sensitizes lung cancer cells to the antitumor activity of cisplatin [34] ; in contrast, several other studies have shown that SIRT1 inhibition sensitizes lung and several other cancer types to the antitumor activity of cisplatin [19, 23, 30, [35] [36] [37] . Despite these findings, it is largely unknown for the role of SIRT1 in NSCLC tumor growth and progression, and the relationship between SIRT1 and p27 kip1 in the control of NSCLC growth and progression has not been established.
This study demonstrates for the first time that SIRT1 is a critical regulator of p27 kip1 reduction in NSCLC; it is shown that SIRT1 promotes p27 kip1 degradation through the ubiquitin-proteolysis pathway. We find that SIRT1 silencing or inhibition suppresses NSCLC proliferation and induces senescence in NSCLC cells, and we demonstrate that p27 kip1 is required for SIRT1-silencing-mediated cell senescence. Furthermore, we demonstrate that SIRT1 silencing dramatically suppresses NSCLC tumor formation in xenograft mouse models. Thus, we discover SIRT1 as a new regulator of p27 kip1 degradation and identify a novel route of senescence induction in NSCLC cancer cells via the SIRT1-p27 kip1 pathway. Our results suggest the SIRT1-p27 kip1 axis plays an important role in controlling NSCLC growth and is a potential target for NSCLC treatment.
Materials and methods

Cell lines, plasmids and antibodies
NSCLC cell lines, including H460, H1299, A549, H1703, H1975, HCC827, and H1993 cells, were obtained from the American Type Culture Collection (Manasses, Virginia).
H1299 and H1703 cells were maintained in 1x RPMI 1640 plus 10% FBS, and H460, A549, H1975, HCC827, and H1993 cells were maintained in 1x DMEM plus 10% FBS.
The human SIRT1 expression vector pcDNA3.1-SIRT1 and the pSUPER.retro.puro-SIRT1 were generated or acquired as previously described [38] . Antibody p27 (3686) mRNA levels were normalized to β-actin. The specificities of the RT-PCR products were monitored by melt curve analysis.
Immunoblotting
Cells were lysed with 1% Nonidet P-40 lysis buffer (1% NP40, 150 mm NaCl, 50 mM
Tris-HCl pH8.0, EDTA 5mM, Na3VO4 1mM ) with protease inhibitor cocktail tablets (Cat#14586500, Roche Diagnostics). Protein samples were subsequently separated on a 12% or 8% SDS PAGE gel and analyzed with anti-SIRT1 (sc-74504, 1000x), anti-p27
(sc-1641, 500x) and anti-β-actin ( A1987, 5000x) antibodies.
In vivo experiments
The mouse work was performed at the Animal Core Facilities of the Boston University into the left flank of nude/nude male mice and the SIRT1-silenced cells were injected s.c.
into the right flank of nude/nude male mice (Charles River Laboratories). The mice were observed every 3 days for the presence of tumors and the tumors were measured weekly with calipers. Each group contained four mice, and two groups of H1299 cells and two groups of H460 cells with independent SIRT1 silencing were studied. The tumor size was calculated based on the formula: 0.52xLxWxH. 
SA-β-Gal analysis
Ki67 Staining of Frozen Tissue Sections
At the endpoint of the in vivo mouse study, the tumors were removed and fixed in 4% 
Results
SIRT1 negatively regulates p27 Kip1 expression
It is well-established that lower levels of p27 kip1 correlate with poor prognosis of NSCLC (Fig. 1A& 1B) . To more specifically study the role of SIRT1 in controlling p27 Kip1 levels, we knocked down SIRT1 in SIRT1-overexpressing NSCLC cells using SIRT1 shRNA to study the effect of SIRT1 silencing on p27 Kip1 expression. Consistent with the data generated by SIRT1 inhibitor treatment, SIRT1 silencing by highly specific genetic methods greatly upregulates p27
Kip1 expression ( Fig. 1C & 1D Fig. 2A & 2B) . The p27 protein half-life was found to increase from 3.5hr to 17hr after SIRT1 silencing in H1299 cells ( Fig. 2A) , and to increase from 3.5hr to 15hr after SIRT1 knockdown in H460 cells (Fig. 2B) . This data suggests that it is the alteration of p27 Kip1 protein stability which is the major cause for increased levels of p27
Kip1 protein expression in SIRT1-silenced cells.
Previous studies have shown that the ubiquitin-proteolysis pathway plays an important role in regulating p27 Kip1 protein levels [1] . After finding that SIRT1 regulates p27 kip1 stability, we next determined whether blocking proteasomal activity would reduce SIRT1-mediated p27 Kip1 downregulation. We ectopically expressed SIRT1 in H1299 cells, which were then treated with MG132 to block proteasome activity, and determined the effects of SIRT1 overexpression on p27 Kip1 expression. While SIRT1 overexpression reduced p27 kip1 levels, blockade of proteasome activity by MG132 produced a dramatic increase in the p27 Kip1 protein levels in SIRT1 ectopically-expressed H1299 cells (Fig. 2C ). This result suggests that blocking proteasome activity by MG132 suppresses SIRT1-mediated p27 kip1 degradation, which is consistent with our other data that shows SIRT1
regulates p27 kip1 degradation through the ubiquitin-proteasome pathway.
SIRT1 inhibition/knockdown suppresses NSCLC proliferation
The role of p27 kip1 in suppressing cell proliferation and inducing cell senescence is well known [1] . After finding the importance of SIRT1 in controlling p27 kip1 expression and stability, we further studied the role of SIRT1 in controlling NSCLC proliferation. We treated a panel of NSCLC cell lines with SIRT1 inhibitors Sirtinol, and found that SIRT1 inhibition significantly decreases NSCLC proliferation in a dose-dependent manner (Fig.   3A) . To validate the SIRT1 specificity of these results, we performed SIRT1 silencing by shRNA to study the effect of SIRT1 silencing on NSCLC proliferation. Responses similar to those of the SIRT1 inhibitor treatment experiment were seen, in that NSCLC proliferation was significantly suppressed by SIRT1 silencing (Fig. 3B) .
SIRT1 silencing induces cell senescence through the p27 kip1 pathway
To further study the mechanism by which SIRT1 suppresses NSCLC proliferation, we first performed a SA-β-Gal analysis in SIRT1-silenced and shRNA-control NSCLC cells, including H460, H1299, and A549 cells. We detected much stronger SA-β-Gal positivity in SIRT1-silenced cells than in shRNA-control cells, suggesting that SIRT1 silencing induces cell senescence in NSCLC cells (Fig. 4A) . We also assessed whether SIRT1
silencing induces apoptosis by analyzing PARP cleavage. We observed no obvious difference in PARP cleavage between SIRT1-silenced and shRNA-control NSCLC cells (see supporting data in Fig. S2 ). These results suggest that cell senescence is an important mechanism by which SIRT1 silencing suppresses NSCLC proliferation. P27 kip1 has been shown to play an important role in the induction of cell senescence [42] .
To clearly evaluate p27 Kip1 as a requirement in SIRT1 silencing-mediated cell senescence, we evaluated the effects of depleting p27 kip1 on the ability of SIRT1 inactivation to induce senescence. To this end, we reduced the levels of p27 Kip1 in SIRT1-silenced NSCLC cells using two independent p27
Kip1 -specific siRNA to study whether p27 Kip1 depletion would rescue the cell senescent phenotype induced by SIRT1
silencing. P27 kip1 deletion in SIRT1-silenced cells greatly reduced the SA-beta-Gal staining compared to non-targeting siRNA-transfected control cells (Figs. 4B) . This result demonstrates that p27 kip1 is required for SIRT1-silencing mediated cell senescence. Since we have shown that SIRT1 inhibition or silencing induces cell senescence and inhibits NSCLC cell proliferation in vitro, we then examined the effect of SIRT1 silencing on suppression of tumor growth in vivo. We used H460 and H1299 NSCLC cell lines stably-expressing either SIRT1-specific shRNA or a non-targeting control shRNA to determine their respective tendencies for tumor formation and growth in xenograft mouse models. Both the SIRT1-silenced and the shRNA-control cells were injected into the same immunocompromised nu/nu mice to exclude individual variation (Fig. 5A & D) .
SIRT1 silencing exhibits strong anti-tumor activity in vivo
We performed two independent tumor injections with H1299 cells and two independent tumor injections with H460 cells, in which the SIRT1-silenced tumor cells were acquired using two specific SIRT1 shRNA expression vectors. We injected 4 mice each for the shRNA control group and for the SIRT1 silenced group. The results show that while 4 out of 4 H460 shRNA control cells formed tumors, only 1 out of 4 H460 SIRT1-silenced H460 mouse cells formed tumors; additionally, the tumorigenic growth of SIRT1-silenced cells was significantly retarded when compared with that of shRNA-control cancer cells (Fig. 5B) . Similar results were obtained from another independent H460 group: while 4 out of 4 control injected mice formed tumors, only 2 out of 4 SIRT1-silenced mouse cells formed tumors, and the tumor growth in the SIRT1-silenced cells was greatly reduced (Fig. 5C ). In parallel with these H460 studies, we also performed two independent experiments with SIRT1-silenced and shRNA-control H1299 cells. The tumor formation rate of control cells was 8 out of 8 (100%), while the rate for SIRT1-silenced cells was 2 out of 8, and the tumor volume of SIRT1 knockdown tumors was greatly reduced compared to that of shRNA control H1299 cells (Figs. 5D, E & F) . This data demonstrates that SIRT1 silencing has a dramatic effect on inhibiting lung tumor formation and growth in vivo in xenograft mouse models. At the endpoint of the mouse model experiment, we isolated the tumors and analyzed SIRT1 and p27 kip1 levels by immunoblot analysis. The data shows that small tumor size correlated with SIRT1 
silencing and p27 kip1 upregulation (Fig. 5G & H) . We also show that SIRT1-silenced tumors had a lower proliferating cell fraction, as determined by IHC detection of Ki67 (Fig. 5I) . Collectively, these results demonstrate that SIRT1 knockdown greatly reduces tumor formation and growth in NSCLC cells, and that p27 kip1 is an important downstream target of SIRT1.
Discussion
This study presents three new findings with important therapeutic implications. First, SIRT1 is a regulator of p27 kip1 expression by controlling p27 kip1 stability through the ubiquitin-proteolysis pathway, and SIRT1 inhibition can upregulate p27 kip1 expression.
Targeting SIRT1 could therefore be a novel strategy for moderating p27 kip1 levels in cancer cells. Second, we show that SIRT1 silencing can induce cell senescence in NSCLC, and that this response is dependent on p27 kip1
. Thus, we demonstrate a new route for senescence induction in established tumors. Third, we show that SIRT1 silencing profoundly suppresses NSCLC tumor formation and growth in vivo, and SIRT1
silencing-mediated growth suppression is associated with upregulated p27 kip1 levels.
Thus, our results suggest that SIRT1 inhibition could be a potential strategy for NSCLC treatment via its upregulation of p27 kip1 expression.
SIRT1 induces p27-dependent, but p53-or p16-independent, cell senescence
Our data shows that SIRT1 regulates p27 kip1 expression by controlling p27 regulation [42, 43] . Several studies have shown that SIRT1 inhibition increases p53 acetylation or upregulates p16 expression to induce cell senescence in endothelial cells or fibroblasts [44, 45] . In NSCLC, a large percentage of cells contain either deleted or mutated p16 or p53, while p27 kip1 remains intact [46] . In the NSCLC cells we studied, 5 out of 7 cell lines had p53 deletion or mutation (Supplementary data Table S1 ) and only 2 out of 7 (H460, A549) had wild-type p53. The p16 pathway was largely disrupted either through deletion (H460, A549 and H1993), methylation (H1299 and HCC827), or mutation (H1975) (Supplementary data Table S1 ). Our result shows that SIRT1
silencing can induce cell senescence in p53-deficient or p16-deficient cells lines, suggesting that the p53-p21 axis or p16 alone cannot be the only mediator of cell senescence after SIRT1 silencing. To test whether the p53-p21 pathway may be involved in SIRT1 silencing-mediated cell senescence in p53 wild-type cells, we checked the acetylated p53 and p21 levels in H460 cells. The results show that although SIRT1 silencing can increase acetylated p53 levels, the level of the p53-responsive gene p21 is downregulated instead of upregulated (supporting data Fig. S3A ). This is consistent with the report that adriamycin-induced p21 protein levels were not higher in SIRT1 Δ/Δ and SIRT1 Δex4/Δex4 MEFs than in the corresponding WT and heterozygous MEFs [47] , although there are other reports which show that p53 hyperacetylation in response to overexpression of a dominant-negative SIRT1 protein was accompanied by increased induction of the p53-responsive gene p21 [20] . In addition to p53, our data also shows that SIRT1 silencing can induce cell senescence in p16-deficient cell lines (H460 and A549) (supporting data Fig. S3B ), indicating that p16 also does not play an important role in SIRT1 silencing-mediated cell senescence. Collectively, these findings suggest that p27 kip1 rather than the p53-p21 pathway or p16 plays an important role in SIRT1
inhibition-mediated cell senescence. Thus, we have identified a new route for cell senescence induction through the SIRT1-p27 pathway in NSCLC cells. 
SIRT1 inhibition is a potential consideration for NSCLC therapy
Cell senescence plays an important role in cancer development and progression [48] , and therapy-induced senescence (TIS) has emerged as a novel therapeutic approach for cancer eradication [42, 49, 50] . Several 
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